Clinical Trial Update: A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure. [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing Aleglitazar with pioglitazone (Actos) in patients with type 2 diabetes and NYHA class II heart failure has completed. The update notes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• Actos (Pioglitazone)
• Aleglitazar (Aleglitazar)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diabetes Mellitus Type 2 | Phase 2 | Status: COMPLETED